Group 1 - The core point of the news is that Weili Medical's stock price increased by 5.13% to 14.76 CNY per share, with a trading volume of 102 million CNY and a turnover rate of 2.44%, resulting in a total market capitalization of 4.308 billion CNY [1] - Weili Medical, established on April 30, 2004, and listed on March 2, 2015, specializes in the research, production, and sales of medical devices in various fields including anesthesia, urology, catheterization, nursing, respiratory care, and dialysis [1] - The revenue composition of Weili Medical is as follows: anesthesia 31.62%, catheterization 29.03%, urology 14.32%, nursing 11.45%, respiratory care 5.56%, dialysis 5.01%, and others 3.01% [1] Group 2 - From the perspective of Weili Medical's top ten circulating shareholders, a fund under China Merchants Fund, specifically the China Merchants Quantitative Selected Stock Initiation A (001917), entered the top ten circulating shareholders in the third quarter, holding 1.8866 million shares, which accounts for 0.65% of the circulating shares [2] - The estimated floating profit for this fund today is approximately 1.3584 million CNY [2] - The China Merchants Quantitative Selected Stock Initiation A (001917) was established on March 15, 2016, with a latest scale of 2.765 billion CNY, achieving a year-to-date return of 40.44% and a one-year return of 47.04% [2]

Core Points - Vili Medical's stock increased by 5.04% to 14.17 CNY per share, with a trading volume of 51.81 million CNY and a turnover rate of 1.27%, resulting in a total market capitalization of 4.15 billion CNY [1] - The company, established on April 30, 2004, and listed on March 2, 2015, specializes in the research, production, and sales of medical devices in various fields including anesthesia, urology, catheterization, nursing, respiratory care, and dialysis [1] - The revenue composition of Vili Medical is as follows: anesthesia 31.62%, catheterization 29.03%, urology 14.32%, nursing 11.45%, respiratory care 5.56%, dialysis 5.01%, and others 3.01% [1] Fund Holdings - The Xinda Australia Fund has a significant holding in Vili Medical, with the Xinda Small and Medium Cap Mixed A Fund (610004) reducing its stake by 69.96 thousand shares in the second quarter, now holding 77.05 thousand shares, which represents 4.54% of the fund's net value [2] - The fund has achieved a floating profit of approximately 523.9 thousand CNY as of the latest report [2] - The Xinda Small and Medium Cap Mixed A Fund was established on December 1, 2009, with a current size of 216 million CNY, and has recorded a year-to-date return of 24.01% [2] Fund Management - The fund is managed by Zeng Guofu and Li Diandian, with Zeng having a tenure of 17 years and 88 days, overseeing assets totaling 481 million CNY, achieving a best return of 109.1% during his tenure [3] - Li Diandian has been managing the fund for 1 year and 7 days, with assets of 570 million CNY, and has achieved a best return of 35.83% during his management period [3]

Core Insights - The company reported a revenue of 745 million yuan for the first half of 2025, representing a year-on-year growth of 10.19% [1] - The net profit attributable to shareholders reached 121 million yuan, with a year-on-year increase of 14.17% [1] Company Overview - The company, Weili Medical, specializes in the research, production, and sales of medical devices in various fields including anesthesia, catheterization, urology, nursing, respiratory care, and blood dialysis [1] - Its products are widely used in clinical settings for general open surgeries, minimally invasive surgeries, emergency care, and nursing [1]